Genetic variants in anti-Müllerian hormone-related genes and breast cancer risk: results from the AMBER consortium
- 22 September 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 185 (2), 469-478
- https://doi.org/10.1007/s10549-020-05944-4
Abstract
Purpose Circulating anti-Müllerian hormone (AMH) levels are positively associated with time to menopause and breast cancer risk. We examined breast cancer associations with single nucleotide polymorphisms (SNPs) in the AMH gene or its receptor genes, ACVR1 and AMHR2, among African American women. Methods In the AMBER consortium, we tested 65 candidate SNPs, and 1130 total variants, in or near AMH, ACVR1, and AMHR2 and breast cancer risk. Overall, 3649 cases and 4230 controls contributed to analyses. Odds ratios (OR) and 95% confidence intervals (CI) for breast cancer were calculated using multivariable logistic regression. Results After correction for multiple comparisons (false-discovery rate of 5%), there were no statistically significant associations with breast cancer risk. Without correction for multiple testing, four candidate SNPs in ACVR1 and one near AMH were associated with breast cancer risk. In ACVR1, rs13395576[C] was associated with lower breast cancer risk overall (OR 0.84; 95% CI 0.72, 0.97) and for ER+ disease (OR 0.75; CI 0.62, 0.89) (p < 0.05). Rs1220110[A] and rs1220134[T] each had ORs of 0.89–0.90 for postmenopausal and ER+ breast cancer (p ≤ 0.03). Conversely, rs1682130[T] was associated with higher risk of ER+ breast cancer (OR 1.17; 95% CI 1.04, 1.32). Near AMH, rs6510652[T] had ORs of 0.85–0.90 for breast cancer overall and after menopause (p ≤ 0.02). Conclusions The present results, from a large study of African American women, provide limited support for an association between AMH-related polymorphisms and breast cancer risk and require replication in other studies.Keywords
Funding Information
- National Center for Advancing Translational Sciences (KL2-TR001109)
- National Cancer Institute (U01 CA179715, R01 CA100598, R01 CA098663, UM1 CA164974, P50 CA58223, P01 CA151135)
- National Cancer Institute (U01 CA179715, R01 CA100598, R01 CA098663, UM1 CA164974, P50 CA58223, P01 CA151135)
This publication has 28 references indexed in Scilit:
- Rethinking sources of representative controls for the conduct of case–control studies in minority populationsBMC Medical Research Methodology, 2013
- Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studiesThe Lancet Oncology, 2012
- Anti-Müllerian hormone: an ovarian reserve marker in primary ovarian insufficiencyNature Reviews Endocrinology, 2012
- Conducting Molecular Epidemiological Research in the Age of HIPAA: A Multi-Institutional Case-Control Study of Breast Cancer in African-American and European-American WomenJournal of Oncology, 2009
- Prospective Case-Control Study of Serum Mullerian Inhibiting Substance and Breast Cancer RiskJNCI Journal of the National Cancer Institute, 2009
- A Flexible and Accurate Genotype Imputation Method for the Next Generation of Genome-Wide Association StudiesPLoS Genetics, 2009
- Association between the candidate susceptibility gene ACVR2A on chromosome 2q22 and pre-eclampsia in a large Norwegian population-based study (the HUNT study)European Journal of Human Genetics, 2008
- PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage AnalysesAmerican Journal of Human Genetics, 2007
- Principal components analysis corrects for stratification in genome-wide association studiesNature Genetics, 2006
- The Structure of Haplotype Blocks in the Human GenomeScience, 2002